Conference Proceedings
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel
Charalambos Andreadis, Constantine S Tam, Peter Borchmann, Ulrich Jaeger, Joseph P McGuirk, Harald Holte, Edmund K Waller, Samantha Jaglowski, Michael R Bishop, Stephen Ronan Foley, Jason R Westin, Isabelle Fleury, P Joy Ho, Stephan Mielke, Takanori Teshima, Gilles A Salles, Stephen J Schuster, Veronika Bachanova, Richard T Maziarz, Koen Van Besien Show all
BLOOD | AMER SOC HEMATOLOGY | Published : 2019
Abstract
Background: Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor (CAR)-T cell therapy that is approved for adult patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). In the phase 2 JULIET trial, pts could receive bridging therapy (BT), when needed, to permit flexibility in scheduling and maintain disease control. Lymphodepleting chemotherapy (LDC) was started 5-14 days prior to CAR-T cell infusion. Here we present baseline characteristics, efficacy/safety outcomes, and cellular kinetics by BT and type of LDC used in the JULIET trial. Methods: Pts were categorized based on BT or no BT, as well as LDC (cyclophosphamide/fludarabine [..
View full abstract